Mesa Laboratories, Inc.
DB:MLI Rapport sur les actions
Capitalisation boursière : €578.1m
Mesa Laboratories Bilan de santé
Santé financière contrôle des critères 2/6 Mesa Laboratories possède un total de capitaux propres de $161.5M et une dette totale de $205.0M, ce qui porte son ratio d'endettement à 127%. Son actif total et son passif total sont $454.1M et de $292.6M. L'EBIT de Mesa Laboratories est $14.7M ce qui fait que son ratio de couverture des intérêts 1.5. Elle dispose de liquidités et de placements à court terme de $26.0M.
Informations clés
127.0%
Ratio d'endettement
Ratio de couverture des intérêts 1.5x Argent liquide US$26.00m Fonds propres US$161.45m Total du passif US$292.65m Total des actifs US$454.10m
Mises à jour récentes de la santé financière
Mesa Laboratories, Inc. announced delayed annual 10-K filing Jun 16 Mesa Laboratories, Inc. announced delayed annual 10-K filing Jun 15
Afficher toutes les mises à jour
Second quarter 2025 earnings released: EPS: US$0.63 (vs US$0.23 loss in 2Q 2024) Nov 08
CEO, President & Director recently sold €529k worth of stock Nov 01
First quarter dividend of US$0.16 announced Oct 06
Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 16, 2024 Oct 03
Fourth quarter dividend of US$0.16 announced Jul 29
Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024 Jul 22
Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on September 16, 2024 Jul 09
Mesa Laboratories, Inc. announced delayed annual 10-K filing Jun 16 Mesa Laboratories, Inc. announced delayed annual 10-K filing Jun 15
Full year 2024 earnings released: US$47.21 loss per share (vs US$0.17 profit in FY 2023) Jun 06
Mesa Laboratories, Inc. Reports Impairment of Goodwill and Long-Lived Assets for the Fourth Quarter Ended March 31, 2024 Jun 06
New minor risk - Share price stability May 31
Upcoming dividend of US$0.16 per share May 24
Third quarter dividend of US$0.16 announced Apr 15
Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024 Apr 05
New minor risk - Share price stability Apr 03
Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024 Apr 02
Upcoming dividend of US$0.16 per share Feb 21
Third quarter 2024 earnings released: EPS: US$0.39 (vs US$0.084 in 3Q 2023) Feb 05
Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors Jan 08
Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024 Jan 05
Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024 Dec 15
Upcoming dividend of US$0.16 per share at 0.7% yield Nov 22
New minor risk - Share price stability Nov 15
Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.24 profit in 2Q 2023) Nov 07 Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million. Oct 18
Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million. Oct 17
Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2023 Oct 05
Mesa Laboratories, Inc. to Report Q2, 2024 Results on Nov 06, 2023 Sep 14
Upcoming dividend of US$0.16 per share at 0.5% yield Aug 23
First quarter 2024 earnings released: US$0.10 loss per share (vs US$0.27 loss in 1Q 2023) Aug 06
New minor risk - Shareholder dilution Jul 20
Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023 Jul 15
Mesa Laboratories, Inc. to Report Q1, 2024 Results on Aug 03, 2023 Jun 22
Full year 2023 earnings released: EPS: US$0.17 (vs US$0.36 in FY 2022) May 26
Now 24% undervalued after recent price drop May 25
Upcoming dividend of US$0.16 per share at 0.4% yield May 23
Mesa Laboratories, Inc. Announces John B. Schmieder, Member of the Board of Directors, Chair of the Nominating and Governance Committee, and Member of the Audit Committee Decide Not to Stand for Re-Election May 10
Upcoming dividend of US$0.16 per share at 0.4% yield Feb 20
Third quarter 2023 earnings released: EPS: US$0.084 (vs US$0.39 loss in 3Q 2022) Feb 08
Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 15, 2023 Jan 04
Mesa Laboratories, Inc. to Report Q3, 2023 Results on Feb 06, 2023 Dec 17
Now 21% undervalued after recent price drop Dec 01
Upcoming dividend of US$0.16 per share Nov 22
Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Substantially all of the assets and certain liabilities from Belyntic GmbH. Nov 18 Mesa Laboratories, Inc. Appoints Tony Tripeny as Member of Audit Committee
Second quarter 2023 earnings released: EPS: US$0.24 (vs US$0.71 in 2Q 2022) Nov 04
Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2022 Oct 04
Upcoming dividend of US$0.16 per share Aug 23
Independent Director recently sold €196k worth of stock Aug 20
Independent Director recently bought €98k worth of stock Aug 10
First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.39 profit in 1Q 2022) Aug 05
Mesa Laboratories, Inc., Annual General Meeting, Jul 26, 2022 Jul 15
Mesa Labs Declares Quarterly Dividend, Payable on September 15, 2022 Jul 07
Mesa Laboratories, Inc. Appoints Tony Tripeny to Its Board of Directors Jun 28
CEO, President & Director recently sold €313k worth of stock Jun 23
Full year 2022 earnings released Jun 01
Upcoming dividend of US$0.16 per share May 20
Mesa Laboratories, Inc. Announces Termination of Greg DiNoia as Senior Vice President of Commercial Operations, Effective June 30, 2022 Apr 12
Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 15, 2022 Apr 07
Upcoming dividend of US$0.16 per share Feb 18
Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 04
Upcoming dividend of US$0.16 per share Nov 22
Insider recently sold €78k worth of stock Nov 10
Second quarter 2022 earnings released: EPS US$0.71 (vs US$0.52 in 2Q 2021) Nov 05
Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Agena Bioscience, Inc. from its shareholders for approximately $300 million. Sep 15
Independent Director recently sold €137k worth of stock Sep 03
Upcoming dividend of US$0.16 per share Aug 23
Insider recently sold €152k worth of stock Aug 13 Mesa Laboratories, Inc.(NasdaqGS:MLAB) dropped from Russell Small Cap Comp Growth Index
CEO, President & Director recently sold €1.4m worth of stock Jun 18
CEO, President & Director recently sold €292k worth of stock Jun 09
Full year 2021 earnings released: EPS US$0.66 (vs US$0.32 in FY 2020) Jun 03
Upcoming dividend of US$0.16 per share May 20
New 90-day low: €216 Mar 09
Insider recently sold €64k worth of stock Feb 25
Upcoming Dividend of US$0.16 Per Share Feb 18
Third quarter 2021 earnings released: US$0.89 loss per share (vs US$1.06 loss in 3Q 2020) Feb 04
Revenue beats expectations Feb 04
New 90-day high: €246 Jan 14
Independent Director recently sold €58k worth of stock Dec 15
New 90-day high: €240 Nov 19
Chairman of the Board recently sold €289k worth of stock Nov 13
Second quarter 2021 earnings released: EPS US$0.52 Nov 07
Revenue beats expectations Nov 07
Mesa Laboratories, Inc. Announces Board Changes Oct 02
New 90-day high: €212 Sep 29
Insider recently sold €57.8k worth of stock Sep 10
Mesa Laboratories, Inc.(NasdaqGS:MLAB) dropped from Russell 2000 Dynamic Index Jul 03
Analyse de la situation financière
Passif à court terme: Les actifs à court terme de MLI ( $108.0M ) ne couvrent pas ses passifs à court terme ( $153.2M ).
Passif à long terme: Les actifs à court terme de MLI ( $108.0M ) ne couvrent pas ses passifs à long terme ( $139.4M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de MLI ( 110.9% ) est considéré comme élevé .
Réduire la dette: Le ratio d'endettement de MLI est passé de 60.1% à 127% au cours des 5 dernières années.
Analyse des pistes de trésorerie Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: Bien que non rentable MLI dispose d'une piste de trésorerie suffisante pour plus de 3 ans si elle maintient son niveau actuel de flux de trésorerie disponible positif.
Prévisions de trésorerie: MLI n'est pas rentable mais dispose d'une marge de trésorerie suffisante pour plus de 3 ans, grâce à un flux de trésorerie disponible positif et en croissance de 5.7 % par an.
Découvrir des entreprises saines Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}